drugset / Trial / NCT03498456
Triple Therapy With Tegoprazan in H. Pylori Positive Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy (lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan after oral administration of the therapy for 7 days, twice daily in H. pylori positive patients.
Timeline
- Start
- 2018-06-28
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 50 mg | Oral |
| Comparator | Amoxicillin | Other / unclassified | 1000 mg | Oral |
| Comparator | Clarithromycin | Small molecule | 500 mg | Oral |